Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.59 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376179 | 0.86 | TGFBR1 (0.67) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| Fluoromethane SCHEMBL27755992 | 0.84 | TGFBR1 (0.64) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL29547877 | 0.84 | TGFBR1 (0.56) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL373665 | 0.84 | TGFBR1 (0.56) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL29504909 | 0.84 | TGFBR1 (0.56) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL23409663 | 0.83 | TGFBR1 (0.54) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL2044324 | 0.81 | TGFBR1 (0.47) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL373583 | 0.79 | MAPK14 (0.55) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL2049077 | 0.77 | TGFBR1 (0.43) | TGFBR1MAPK14THRB | |
| SCHEMBL18292297 | 0.77 | NFATC1 (0.51) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | claimed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | claimed |
| EP-1959949-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | Alcon, Inc. (CH) | 2008-08-27 | — | — | EP | claimed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | claimed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | claimed |
| WO-2004026302-A1 | METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B&G PARTNERS, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2409708-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partners, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | disclosed |
| EP-1959949-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | Alcon, Inc. (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2004026302-A1 | METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885TGFBR2 332/4885 |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885TGFBR2 18/4885 |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885TGFBR2 18/4885 |
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | TGFBR1 106/4885MAPK14 1923/4885TGFBR2 59/4885 |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885TGFBR2 332/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885TGFBR2 18/4885 |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | MUC1, NEU4, ALK | TGFBR1 1324/4885MAPK14 2025/4885TGFBR2 1798/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | TGFBR1 75/4885MAPK14 1174/4885TGFBR2 87/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885TGFBR2 332/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | TGFBR1 5/4885MAPK14 1007/4885TGFBR2 3/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885TGFBR2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.